» Articles » PMID: 33662039

Radon-220 Diffusion from 224Ra-labeled Calcium Carbonate Microparticles: Some Implications for Radiotherapeutic Use

Overview
Journal PLoS One
Date 2021 Mar 4
PMID 33662039
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha-particle emitting radionuclides continue to be the subject of medical research because of their high energy and short range of action that facilitate effective cancer therapies. Radium-224 (224Ra) is one such candidate that has been considered for use in combating micrometastatic disease. In our prior studies, a suspension of 224Ra-labeled calcium carbonate (CaCO3) microparticles was designed as a local therapy for disseminated cancers in the peritoneal cavity. The progenies of 224Ra, of which radon-220 (220Rn) is the first, together contribute three of the four alpha particles in the decay chain. The proximity of the progenies to the delivery site at the time of decay of the 224Ra-CaCO3 microparticles can impact its therapeutic efficacy. In this study, we show that the diffusion of 220Rn was reduced in labeled CaCO3 suspensions as compared with cationic 224Ra solutions, both in air and liquid volumes. Furthermore, free-floating lead-212 (212Pb), which is generated from released 220Rn, had the potential to be re-adsorbed onto CaCO3 microparticles. Under conditions mimicking an in vivo environment, more than 70% of the 212Pb was adsorbed onto the CaCO3 at microparticle concentrations above 1 mg/mL. Further, the diffusion of 220Rn seemed to occur whether the microparticles were labeled by the surface adsorption of 224Ra or if the 224Ra was incorporated into the bulk of the microparticles. The therapeutic benefit of differently labeled 224Ra-CaCO3 microparticles after intraperitoneal administration was similar when examined in mice bearing intraperitoneal ovarian cancer xenografts. In conclusion, both the release of 220Rn and re-adsorption of 212Pb are features that have implications for the radiotherapeutic use of 224Ra-labeled CaCO3 microparticles. The release of 220Rn through diffusion may extend the effective range of alpha-particle dose deposition, and the re-adsorption of the longer lived 212Pb onto the CaCO3 microparticles may enhance the retention of this nuclide in the peritoneal cavity.

Citing Articles

Eighteen-Months Safety and Efficacy Following Intraperitoneal Treatment With Radium-Labeled Microparticles After CRS-HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer.

Larsen S, Graf W, Larsen R, Revheim M, Mariathasan A, Sorensen O J Surg Oncol. 2024; 130(6):1395-1402.

PMID: 39428687 PMC: 11826020. DOI: 10.1002/jso.27897.


Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.

Trencsenyi G, Csikos C, Kepes Z Int J Mol Sci. 2024; 25(1).

PMID: 38203834 PMC: 10779852. DOI: 10.3390/ijms25010664.


Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis.

Gronningsaeter S, Blakkisrud J, Selboe S, Revheim M, Bruland O, Bonsdorff T Front Med (Lausanne). 2023; 10:1058914.

PMID: 36844217 PMC: 9945525. DOI: 10.3389/fmed.2023.1058914.


Dual targeting with Ra/Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach.

Juzeniene A, Stenberg V, Bruland O, Revheim M, Larsen R Front Med (Lausanne). 2023; 9:1051825.

PMID: 36733936 PMC: 9887039. DOI: 10.3389/fmed.2022.1051825.


Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [Ra]RaCl and [Ra]RaCl.

Lassmann M, Eberlein U Front Med (Lausanne). 2023; 9:1057373.

PMID: 36687439 PMC: 9847387. DOI: 10.3389/fmed.2022.1057373.


References
1.
Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I . Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol. 2007; 52(16):5025-42. DOI: 10.1088/0031-9155/52/16/021. View

2.
Popovtzer A, Rosenfeld E, Mizrachi A, Bellia S, Ben-Hur R, Feliciani G . Initial Safety and Tumor Control Results From a "First-in-Human" Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head and Neck. Int J Radiat Oncol Biol Phys. 2019; 106(3):571-578. DOI: 10.1016/j.ijrobp.2019.10.048. View

3.
Napoli E, Stenberg V, Juzeniene A, Hjellum G, Bruland O, Larsen R . Calibration of sodium iodide detectors and reentrant ionization chambers for Pb activity in different geometries by HPGe activity determined samples. Appl Radiat Isot. 2020; 166:109362. DOI: 10.1016/j.apradiso.2020.109362. View

4.
Volodkin D, Petrov A, Prevot M, Sukhorukov G . Matrix polyelectrolyte microcapsules: new system for macromolecule encapsulation. Langmuir. 2005; 20(8):3398-406. DOI: 10.1021/la036177z. View

5.
Sgouros G, Bodei L, McDevitt M, Nedrow J . Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020; 19(9):589-608. PMC: 7390460. DOI: 10.1038/s41573-020-0073-9. View